Seed Round Investment- MedTech Device in Foot Ulcer Early Detection and Characterization

Diabetic Foot ulceration is a growing global epidemic, with over 45 million ulcers occurring every year. Its extremely costly, and disruptive to the patients, commonly ending up with amputation and death.

DiabSense is focused on early detection of foot ulcers at home with a household device, and foot characterization at hospital with an advanced scanner, both equipped with thermal imaging and backend AI. The system will offer a comprehensive solution for foot ulcer early detection and prevention.
We have completed 2nd prototype batch, and now in pre-clinical testing with promising results. We expect to launch in 2029, and capture a SOM of 220Million in 5 years (and continue to keep rapid growth for a decade to come).

Our team has 5 years of experience in similar medical product development, clinical and certification to US / Europe customers, therefore we are quite capable of fast track development and launch. A comprehensive team is already working full time on this project.

The market is almost empty, with only viable competition is from Podimatrics, launched recently in US in small scale (no viable solution available anywhere else). Our patented solution is much more comprehensive, offers full protection for patients and provide remote connectivity / analytics to doctors.

We are currently bootstrapped, offering 15% of the company for 1.6 Million Euro seed investment. For Seed round investments, we expect an ARR of over 30%.